



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Melanoma - 5EU Drug Forecast and Market Analysis to 2023

Melanoma - 5EU Drug Forecast and Market Analysis to 2023

Publication ID:

GDA0415188

Publication Date:

April 05, 2015

Pages:

281

Publisher:

GlobalData

Region:

Europe [1]

\$6,995.00

Publication License Type *

Single User License (PDF), \$6,995.00

Site License (PDF), \$13,990.00

Global License (PDF), \$20,985.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

Melanoma - 5EU Drug Forecast and Market Analysis to 2023

Summary

Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. GlobalData estimates the 2013 sales for melanoma at approximately \$1.34 billion across the 8MM covered in this report. The market will increase by four-fold over the forecast period, reaching \$5.64 billion in 2023 at a CAGR of 15.5%. This growth will be driven by an increase in melanoma incident cases as well as the approval and uptake of premium-priced products, such as PD-1-targeting mAbs and BRAF/MEK inhibitor combinations. GlobalData expects, by the end of the forecast period, the checkpoint immunotherapy drug class to dominate the melanoma market (including both BRAF wild-type and mutation-positive patient segments) with an overall 67% share of the melanoma market.

GlobalData forecasts the melanoma market in the 5EU to increase from \$373m in 2013. The melanoma branded market in the 5EU in the base year was small because there were only three approved brands, Yervoy, Zelboraf, and Tafinlar, and Tafinlar was only approved in Q4 2013. The growth of the 5EU market is expected to be driven by increasing disease incident cases and the launch of new regimens, such as label expansion of Yervoy into the first-line setting, BRAF/MEK inhibitor combinations, anti-PD-1 immunotherapies, and the Yervoy/Opdivo combination. However, GlobalData expects that the cost consciousness of the European healthcare systems, as well as the difficulties in getting reimbursement approval in individual European countries, will limit the growth of the melanoma branded market.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Overview of Melanoma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product Melanomacription, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Melanoma market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Melanoma.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in 5EU.

Table Of Contents:

1	Table of Contents	
1	Table of Contents 2	
1.1	List of Tables	7
1.2	List of Figures	12
2	Introduction	14
2.1	Catalyst	14
2.2	Related Reports	15
2.3	Upcoming Related Reports	15
3	Disease Overview	16
3.1	Etiology and Pathophysiology	16
3.1.1	Etiology	16
3.1.2	Pathophysiology	16
3.1.3	Melanoma Biomarkers	17
3.2	Clinical Staging	18
3.3	Symptoms	20
3.4	Prognosis	20
3.5	Quality of Life	22
4	Disease Management	23
4.1	Diagnosis Overview	23
4.2	Treatment Overview	24
4.2.1	Localized Melanoma: Stage 0 to Stage IIC	26
4.2.2	Regional Melanoma: Stage IIIA to Stage IIIC	27
4.2.3	Unresectable and Metastatic Melanoma: Stage III and Stage IV	30
4.3	France	37
4.3.1	Screening and Diagnosis	38
4.3.2	Clinical Practices	38
4.4	Germany	40
4.4.1	Screening and Diagnosis	41
4.4.2	Clinical Practices	42
4.5	Italy	44
4.5.1	Screening and Diagnosis	45
4.5.2	Clinical Practices	45
4.6	Spain	47
4.6.1	Screening and Diagnosis	48
4.6.2	Clinical Practices	48
4.7	UK	49

4.7.1	Screening and Diagnosis	50
4.7.2	Clinical Practices	50
5	Competitive Assessment	52
5.1	Overview	52
5.2	Interferon-based Adjuvant Therapies	54
5.2.1	Roferon-A (Interferon Alfa-2a)	54
5.2.2	Intron A (Interferon Alfa-2b)	58
5.2.3	Sylatron (Peginterferon Alfa-2b)	63
5.3	Immune Checkpoint Inhibitors	69
5.3.1	Yervoy (Ipilimumab)	69
5.3.2	Opdivo (Nivolumab)	79
5.3.3	Keytruda (Pembrolizumab)	88
5.4	BRAF Mutation-targeted Therapies	96
5.4.1	Zelboraf (Vemurafenib)	96
5.4.2	Tafinlar (Dabrafenib)	103
5.4.3	Mekinist (Trametinib)	109
5.5	Other Therapeutic Classes	120
6	Unmet Need and Opportunity Analysis	122
6.1	Overview	122
6.2	Therapeutic Options for BRAF Wild-Type Patients	124
6.2.1	Unmet Need	124
6.2.2	Gap Analysis	125
6.2.3	Opportunity	126
6.3	Therapies for Non-responders to PD-1 Immunotherapy	127
6.3.1	Unmet Need	127
6.3.2	Gap Analysis	128
6.3.3	Opportunity	130
6.4	Adjuvant Therapies for High-Risk Resectable Melanoma	132
6.4.1	Unmet Need	132
6.4.2	Gap Analysis	133
6.4.3	Opportunity	135
6.5	Effective Treatment for Brain Metastases	137
6.5.1	Unmet Need	137
6.5.2	Gap Analysis	138
6.5.3	Opportunity	140
6.6	Predictive Markers for Therapeutic Response to Immunotherapies	141
6.6.1	Unmet Need	141
6.6.2	Gap Analysis	142
6.6.3	Opportunity	144
7	Pipeline Assessment	145

7.1 Overview	145
7.2 Promising Drugs in Clinical Development	146
7.3 RAF/RAS/MEK Pathway-Targeting Therapies	148
7.3.1 Cobimetinib (GDC-0973)	148
7.3.2 Encorafenib (LGX818)	155
7.3.3 Binimetinib (MEK162)	161
7.4 Immune-Related Therapies	168
7.4.1 Talimogene Laherparepvec	168
7.4.2 Eltrapuldencel-T (NSB20)	176
7.4.3 Seviprotimut-L (POL-103A)	182
7.4.4 PV-10	188
7.5 Promising Drugs in Early-Stage Development	194
7.5.1 PI3K/Akt/mTOR Pathway-Targeting Therapies	194
7.5.2 Cell Cycle Checkpoint Inhibitors	196
7.5.3 Next-Generation BRAF Inhibitors	198
7.5.4 Immunotherapies	200
7.5.5 Antibody-Drug Conjugates	203
7.6 Other Drugs in Development	205
8 Market Outlook	207
8.1 5EU	207
8.1.1 Forecast	207
8.1.2 Key Events	211
8.1.3 Drivers and Barriers - France	212
8.1.4 Drivers and Barriers - Germany	214
8.1.5 Drivers and Barriers - Italy	215
8.1.6 Drivers and Barriers - Spain	217
8.1.7 Drivers and Barriers - UK	218
9 Appendix	221
9.1 Bibliography	221
9.2 Abbreviations	248
9.3 Methodology	253
9.4 Forecasting Methodology	253
9.4.1 Diagnosed Melanoma Patients	253
9.4.2 Percent Drug-Treated Patients	254
9.4.3 Drugs Included in Each Therapeutic Class	254
9.4.4 Launch and Patent Expiry Dates	255
9.4.5 General Pricing Assumptions	256
9.4.6 Average Body Weight and Surface Area Across the 8MM	257
9.4.7 Individual Drug Assumptions	258
9.4.8 Generic Erosion	272

9.4.9 Pricing of Pipeline Agents	272
9.5 Primary Research - KOLs Interviewed for this Report	274
9.6 Primary Research - Prescriber Survey	277
9.7 About the Authors	278
9.7.1 Analyst	278
9.7.2 Therapy Area Director	278
9.7.3 Epidemiologist	279
9.7.4 Global Head of Healthcare	279
9.8 About GlobalData	280
9.9 Disclaimer	280

1.1 List of Tables

Table 1: Stage Definitions for Melanoma	19
Table 2: The ABCED Rule of Melanoma Detection	20
Table 3: Prognosis of Melanoma	21
Table 4: Clinical Guidelines for Melanoma	25
Table 5: Most Prescribed Drugs for Melanoma by Class in the Global Markets, 2013	36
Table 6: Country Profile - France	37
Table 7: Country Profile - Germany	40
Table 8: Country Profile - Italy	44
Table 9: Country Profile - Spain	47
Table 10: Country Profile - UK	49
Table 11: Leading Treatments for Melanoma, 2013	53
Table 12: Product Profile - Roferon-A	55
Table 13: Safety of Roferon-A	56
Table 14: Roferon-A SWOT Analysis, 2015	57
Table 15: Global Sales Forecast (\$m) for Roferon-A, 2013-2023	58
Table 16: Product Profile - Intron A	59
Table 17: Efficacy of Intron A (E1684)	60
Table 18: Safety of Intron A (E1684, E1690, and E1694)	61
Table 19: Intron A SWOT Analysis, 2015	62
Table 20: Global Sales Forecast (\$m) for Intron A, 2013-2023	63
Table 21: Product Profile - Sylatron	65
Table 22: Efficacy of Sylatron (EORTC 18991, NCT00006249)	66
Table 23: Head-to-Head Comparison Between Sylatron and Low-Dose Interferon	67
Table 24: Safety of Sylatron	68
Table 25: Sylatron SWOT Analysis, 2015	68
Table 26: Global Sales Forecast (\$m) for Sylatron, 2013-2023	69
Table 27: Product Profile - Yervoy	71
Table 28: Efficacy of Yervoy	73

Table 29: Comparison of Higher Dose Yervoy and Dacarbazine (NCT00324155)	74
Table 30: Network Meta-analysis of Yervoy	75
Table 31: Safety of Yervoy at 3mg/kg (NCT00094653)	76
Table 32: Safety Data from Yervoy Dose-Escalation Study (NCT00289640)	77
Table 33: Yervoy SWOT Analysis, 2015	78
Table 34: Global Sales Forecast (\$m) for Yervoy, 2013-2023	79
Table 35: Product Profile - Opdivo	82
Table 36: Efficacy of Opdivo	84
Table 37: Efficacy of Opdivo in BRAF Wild-Type Advanced Melanoma (NCT01721772)	85
Table 38: Safety Data from Opdivo Dose-Escalation Study (NCT00730639)	86
Table 39: Safety Data from the CheckMate-037 Trial (NCT01721746)	86
Table 40: Opdivo SWOT Analysis, 2015	87
Table 41: Global Sales Forecast (\$m) for Opdivo, 2013-2023	88
Table 42: Product Profile - Keytruda	91
Table 43: Efficacy of Keytruda from KEYNOTE-001 (NCT01295827)	92
Table 44: Efficacy of Keytruda from KEYNOTE-002 (NCT01704287)	93
Table 45: Safety of Keytruda	94
Table 46: Keytruda SWOT Analysis, 2015	95
Table 47: Global Sales Forecasts (\$m) for Keytruda, 2013-2023	96
Table 48: Product Profile - Zelboraf	98
Table 49: Efficacy of Zelboraf	100
Table 50: Safety of Zelboraf	101
Table 51: Zelboraf SWOT Analysis, 2015	102
Table 52: Global Sales Forecasts (\$m) for Zelboraf, 2013-2023	103
Table 53: Product Profile - Tafinlar	105
Table 54: Efficacy of Tafinlar	106
Table 55: Safety of Tafinlar	107
Table 56: Tafinlar SWOT Analysis, 2015	108
Table 57: Global Sales Forecast (\$m) for Tafinlar, 2013-2023	109
Table 58: Product Profile - Mekinist	112
Table 59: Efficacy of Mekinist	113
Table 60: Efficacy Results of the COMBI-d Trial (NCT01584648)	114
Table 61: Efficacy Results of the COMBI-v Trial (NCT01072175)	115
Table 62: Safety of Mekinist	116
Table 63: Safety Results of the COMBI-d trial (NCT01584648)	117
Table 64: Safety Results of the COMBI-v trial (NCT01584648)	118
Table 65: Mekinist SWOT Analysis, 2015	119
Table 66: Global Sales Forecasts (\$m) for Mekinist, 2013-2023	120
Table 67: Summary of Minor Therapeutic Classes, 2013	121
Table 68: Unmet Needs and Opportunities in Melanoma	124

Table 69: Product Profile - Cobimetinib	150
Table 70: Efficacy of the Zelboraf/Cobimetinib Combination	151
Table 71: Safety of the Zelboraf/Cobimetinib Combination	152
Table 72: Cobimetinib SWOT Analysis, 2015	154
Table 73: Global Sales Forecast (\$m) for Cobimetinib, 2013-2023	155
Table 74: Product Profile - Encorafenib	157
Table 75: Efficacy of Encorafenib	158
Table 76: Encorafenib SWOT Analysis, 2015	160
Table 77: Global Sales Forecasts (\$m) for Encorafenib, 2013-2023	161
Table 78: Product Profile - Binimetinib	163
Table 79: Efficacy of Binimetinib (NCT01320085)	164
Table 80: Safety of Binimetinib (NCT01320085)	165
Table 81: Binimetinib SWOT Analysis, 2015	167
Table 82: Global Sales Forecasts (\$m) for Binimetinib, 2013-2023	168
Table 83: Product Profile - Talimogene Laherparepvec	171
Table 84: Efficacy of Talimogene Laherparepvec	172
Table 85: Safety of Talimogene Laherparepvec	173
Table 86: Talimogene Laherparepvec SWOT Analysis, 2015	175
Table 87: Global Sales Forecast (\$m) for Talimogene Laherparepvec, 2013-2023	176
Table 88: Product Profile - Eltrapuldencel-T	178
Table 89: Efficacy of Eltrapuldencel-T	179
Table 90: Eltrapuldencel-T SWOT Analysis, 2015	181
Table 91: Global Sales Forecast (\$m) for Eltrapuldencel-T, 2013-2023	182
Table 92: Product Profile - Seviprotimut-L	184
Table 93: Efficacy of Seviprotimut-L	185
Table 94: Seviprotimut-L SWOT Analysis, 2015	187
Table 95: Global Sales Forecast (\$m) for Seviprotimut-L, 2013-2023	188
Table 96: Product Profile - PV-10	189
Table 97: Efficacy of PV-10	190
Table 98: Safety of PV-10	191
Table 99: PV-10 SWOT Analysis, 2015	193
Table 100: Global Sales Forecast (\$m) for PV-10, 2013-2023	194
Table 101: Clinical Settings of Early-Stage Drugs Targeting the PI3K/Akt/mTOR Pathway	196
Table 102: Clinical Settings of Early-Stage Drugs Targeting Cell Cycle Checkpoints	198
Table 103: Clinical Settings of Early-Stage Next-Generation BRAF Inhibitors	199
Table 104: Clinical Settings of Early-Stage Immunotherapies	203
Table 105: Clinical Settings of Early-Stage Antibody-drug Conjugates	204
Table 106: Drugs in Development, 2015	205
Table 107: Sales Forecast (\$m) for Melanoma in the 5EU, 2013-2023	209
Table 108: Key Events Impacting Sales for Melanoma in the 5EU, 2013-2023	211

Table 109: Melanoma Market in France - Drivers and Barriers, 2015 212
Table 110: Melanoma Market in Germany - Drivers and Barriers, 2015 214
Table 111: Melanoma Market in Italy - Drivers and Barriers, 2015 215
Table 112: Melanoma Market in Spain - Drivers and Barriers, 2015 217
Table 113: Melanoma Market in the United Kingdom - Drivers and Barriers, 2015 218
Table 114: Key Launch Dates 255
Table 115: Key Patent Expiries 256
Table 116 Average Body Weight and Surface Area Across the 8MM 257
Table 117: High-Prescribing Physicians Surveyed by Country 277

1.2 List of Figures

Figure 1: Treatment Flowchart for Localized Melanoma 27
Figure 2: Treatment Flowchart for Regional Melanoma 28
Figure 3: Treatment Flowchart for Recurrent Melanoma 30
Figure 4: Treatment Flowchart for Metastatic Melanoma 32
Figure 5: Yervoy's Development in Melanoma 72
Figure 6: Opdivo's Development in Melanoma 82
Figure 7: Keytruda's Development in Melanoma 91
Figure 8: Zelboraf's Development in Melanoma 99
Figure 9: Mekinist's Development in Melanoma 112
Figure 10: Melanoma - Phase III Pipeline, 2015 147
Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in Melanoma, 2013-2023 148
Figure 12: Cobimetinib's Development in Melanoma 150
Figure 13: Clinical and Commercial Positioning of Cobimetinib 153
Figure 14: Encorafenib's Development in Melanoma 157
Figure 15: Clinical and Commercial Positioning of Encorafenib 159
Figure 16: Binimetinib's Development in Melanoma 163
Figure 17: Clinical and Commercial Positioning of Binimetinib 166
Figure 18: Talimogene Laherparepvec's Development in Melanoma 171
Figure 19: Clinical and Commercial Positioning of Talimogene Laherparepvec 174
Figure 20: Eltrapuldencel-T's Development in Melanoma 178
Figure 21: Clinical and Commercial Positioning of Eltrapuldencel-T 180
Figure 22: Seviprotimut-L's Development in Melanoma 184
Figure 23: Clinical and Commercial Positioning of Seviprotimut-L 186
Figure 24: PV-10's Development in Melanoma 190
Figure 25: Clinical and Commercial Positioning of PV-10 192
Figure 26: Sales for Melanoma in the EU by Drug Class, 2013-2023 210

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.



Drug Pipeline

No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

About Us

Reports by Region

FAQ

Privacy Policy

TERMS & CONDITIONS

CONTACT

RECENT POSTS

What is drug pipeline research?

March 20

How to use market research to bring your idea to life?

March 11

How to gain business insights using syndicated market research?

March 10

Source URL: <https://www.drugpipeline.net/globaldata/melanoma-5eu-drug-forecast-and-market-analysis-2023>

Links

[1] <https://www.drugpipeline.net/region/europe>